Quality of Life in Head and Neck Cancer Patients: Impact of HPV and Primary Treatment Modality
|
|
- Reynold O’Brien’
- 5 years ago
- Views:
Transcription
1 The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Quality of Life in Head and Neck Cancer Patients: Impact of HPV and Primary Treatment Modality Jessica H. Maxwell, MD, MPH; Vikas Mehta, MD; Hong Wang, PhD; Diana Cunningham, MS; Umamaheswar Duvvuri, MD, PhD; Seungwon Kim, MD; Jonas T. Johnson, MD; Robert L. Ferris, MD, PhD Objectives/Hypothesis: To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. Study Design: Retrospective study. Methods: One hundred and seventy-seven patients (N 5 177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. Results: Of the 177 patients, 80 (45.2%) were p16-positive and 49.7% of subsites were oropharyngeal. Nearly 60% (105/177) of patients underwent primary surgery, 26.7% (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7% of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P ), at 6 months posttreatment (P ), and at greater than 1 year posttreatment (P ). P16-positive patients had better QOL scores in speech (P ), chewing (P ), and swallowing (P ) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. Conclusion: The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Key Words: Quality of life, HPV, p16, head and neck squamous cell carcinoma. Level of Evidence: 4. Laryngoscope, 124: , 2014 INTRODUCTION Human papillomavirus (HPV) is a recently discovered cause of oropharyngeal squamous cell carcinoma (OPSCC) and portends a favorable prognosis. 1,2 Patients with HPV-positive OPSCC tend to be younger, 3 less likely to smoke, 3,4 and have an improved disease-specific and overall survival compared to their HPV-negative counterparts. 1,2,4 The improved survival benefit is seen in HPV-positive patients regardless of primary treatment modality, including primary surgery with or without adjuvant therapy 5 or definitive chemoradiation. 1,2 Because survival is expected among HPV-positive patients and the incidence of HPV-positive OPSCC is increasing, 6 8 the factors that contribute to posttreatment quality of life (QOL) become more important for this particular group of patients. Understanding the relationship between QOL and HPV can also help guide clinicians in clinical management and treatment options. While OPSCC was traditionally treated with upfront chemoradiation, 9 11 primary surgical management is returning to the forefront with the use of transoral, minimally invasive techniques. 12,13 It has yet to be determined how QOL is affected by primary treatment modality among HPVpositive patients. The goal of this study was to determine the role of HPV status and primary treatment modality on QOL in patients with head and neck squamous cell carcinoma. From the Department of Otolaryngology, University of Pittsburgh Medical Center (J.H.M., U.D., S.K., J.J., R.L.F.); the University of Pittsburgh Cancer Institute, Biostatistics Facility (H.W., D.C.), Pittsburgh, Pennsylvania; and the Department of Otolaryngology/Head and Neck surgery, LSUHSC Shreveport (V.M.), Shreveport, Louisiana, U.S.A. Editor s Note: This Manuscript was accepted for publication November 1, The authors have no funding, financial relationships, or conflicts of interest to disclose. Send correspondence to Robert L. Ferris, MD, PhD, Suite 500, 203 Lothrop Street, Pittsburgh, PA 15213; ferrrl@upmc.edu DOI: /lary MATERIALS AND METHODS Study Population After approval was obtained from the institutional review board of the University of Pittsburgh Medical Center (IRB - PRO ), patients with a primary head and neck squamous cell carcinoma diagnosed between 2006 and 2012 at the University of Pittsburgh Medical Center were included in this study. Patients were included only if they had completed at least one University of Washington QOL version 4 (UW-QOL v4) survey at specific time points before and/or after treatment. Known HPV and p16 status by in situ hybridization and
2 immunohistochemistry, respectively, was an additional inclusion criterion for this study. Demographic and clinical data obtained from our prospectively collected head and neck database included age, gender, primary tumor site, clinical and pathological tumor stage, HPV and p16 status, treatment modality, and follow-up time. Tumor stage was defined by the American Joint Committee on Cancer (AJCC version 6). Survival data was not collected or included in the analysis. Among patients who were treated with primary surgery, differences in QOL were analyzed among those who underwent open versus minimally invasive techniques. Minimally invasive techniques included transoral robotic surgery and microsuspension laryngoscopy with laser. Neck dissections were performed, when appropriate, in patients who underwent both open and minimally invasive techniques. HPV and p16 Analysis All patients tumors included in this study were tested for HPV by in-situ hybridization (ISH) and p16 by immunohistochemistry (IHC) at the time of initial diagnosis. HPV detection by in situ hybridization was performed using probes targeting 37 distinct HPV subtypes, including 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, and 52 (Y1404; Dako, Carpinteria, CA). Cases with punctate nuclear signal were considered positive. 14 For p16 analysis, heat-induced epitope retrieval of deparaffinized tumor sections was then performed in a citrate buffer. Immunohistochemistry for p16 (G ; BD Pharmingen, San Diego, CA) was performed as per the manufacturer s protocol. Cases were reviewed by specialized head and neck pathologists and were considered positive if > 70% to 80% of tumor cells showed diffuse, strong cytoplasmic and nuclear staining. 14 P16 status by IHC was used for the statistical analysis. QOL Assessment QOL was assessed using the UW-QOL v4 survey administered before and after treatment. The UW-QOL v4 survey is a validated head and neck cancer-specific health related questionnaire that consists of 12 domain-specific items The 12 domains include pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder function, taste, saliva, mood, and anxiety. The QOL survey also includes the most important domains as perceived by the patient. Each domain item is scored from 0 to 100 with 100 being the best possible response. An overall QOL score was determined by averaging across all 12 domains. Investigators have shown that a 7-point difference in overall QOL score represents the minimal clinically important difference. 18 Patients in the head and neck cancer clinic at the University of Pittsburgh are routinely offered the UW-QOL v4 survey during their clinic visit. Patient QOL surveys were only included for this study if they fell into one of five time periods. These time periods included a baseline survey prior to treatment (within 60 days pretreatment) and four surveys posttreatment at 2 months (6 30 days), 6 months (6 40 days), 1 year (6 60 days), and between 1 and 3 years. Patients with QOL surveys that were completed outside of these time periods were excluded from this study. Patients had to have completed at least one survey in a specified time period to be included in the study, but there was no upper limit to the number of surveys they could complete. To obtain a sufficient sample size, patients were not required to have completed consecutive surveys at each time period in order to be included in the study. Most patients responded to more than one survey; however, only three patients responded to surveys at all five time periods. A change in QOL was calculated by subtracting the difference in QOL scores between two time periods of interest. Statistical Analysis Statistical analysis was performed in SAS 9.3 software (SAS Corp, Cary, NC). To examine differences in patient characteristics by p16 status, primary treatment modality and oropharynx subsite, both Fisher s exact tests and Wilcoxon Mann Whitney tests were used for categorical variables and continuous variables, respectively. When examining changes from baseline, the change in score for each domain was calculated by subtracting the baseline score from the score for the corresponding month for each patient. A positive value would indicate an improvement and a negative value would indicate that conditions worsened for that domain. To determine if the change from baseline was significant, we applied the Wilcoxon sign test. To determine if there were significant differences in scores at each time point between patients with and without surgery, with open versus minimally invasive techniques, by p16 status and oropharynx subsite, Wilcoxon-Mann Whitney exact tests were used. P values of less than 0.05 were considered statistically significant. To determine if there were significant differences in scores at each time point between patients with and without surgery, by p16 status and oropharynx subsite, Wilcoxon-Mann Whitney exact tests were used. P values of less than 0.05 were considered statistically significant. RESULTS One hundred and seventy-seven patients (N 5 177) were included in this study. Nearly half of all patients were p16-positive (45.2%; 80/177). Nearly half of all patients had an oropharyngeal primary tumor (88/177; 49.7%). Approximately 30% of p16-positive patients underwent primary surgical resection (24/80; 30%) compared to 83.5% of p16-negative patients (81/97; P < ). Table I demonstrates clinical and pathological data for all patients in this cohort. Of the 177 patients, 33 responded to a survey at baseline, 62 at 2 months, 86 at 6 months, 77 at 1 year, and 54 at greater than 1 year after initial treatment. There was no statistical difference in the proportion of p16-positive patients with QOL data at each time point. The proportion of p16-positive patients with QOL data ranged from a low of 39.5% at the 1-year time point to a high of 53.8% at the 1- to 3-year time point. Baseline QOL scores differed among p16-positive and p16-negative patients in that p16-positive patients had significantly better scores in overall QOL (P ; Fig. 1), recreation (P 5.004), and chewing (P ; Fig. 2a). At 2 months posttreatment, p16-positive patients had better scores in chewing (P ; Fig. 2a) and speech (P ; Fig. 2b) compared to p16-negative patients. At 6 months posttreatment, p16-positive patients had better activity (P ), recreation (P ), swallowing (P ; Fig. 2c), speech (P ; Fig. 2b), and overall QOL (P ; Fig. 1) compared to p16-negative patients. The benefit for p16- positive patients in activity (P ), recreation (P ), swallowing (P ), chewing (P ), speech (P ), and overall QOL (P ) was maintained between 1 and 3 years posttreatment. In contrast, saliva production was the only domain that 1593
3 TABLE I. Clinical and Pathologic Data of All Patients by p16 Status. p16-positive (n 5 80) p16-negative (n 5 97) Characteristic No. % No. % P value Age (mean) Gender.217 Male Female Tumor subsite <.0001 Oropharynx Nonoropharynx HPV <.0001 Positive Negative Not evaluated T class Tis T T T T Unknown N class <.0001 N N N N Unknown AJCC stage*.001 I II III IV Unknown Primary Treatment <.0001 Surgical Nonsurgical Radiation <.0001 Yes No Chemotherapy <.0001 Yes No *AJCC stage 5 American Joint Committee on Cancer stage. Radiation 5 Includes patients treated with primary radiation and postoperative radiation. Chemotherapy 5 Includes patients treated with primary chemotherapy and postoperative chemotherapy. was significantly better for p16-negative patients compared to p16-positive patients (P ; Fig. 2d) at 2, 6, and 12 months posttreatment. However, this difference was no longer significant after 1 year posttreatment. Among p16-positive patients only, overall QOL scores did not differ by primary treatment modality. Furthermore, primary surgery versus chemoradiation did not affect QOL in any of the 12 domains at any time point among p16-positive patients. Similarly, among p16-negative patients, primary treatment modality did not affect baseline or posttreatment overall QOL. However, at 2 months posttreatment for p16-negative 1594
4 techniques. In p16-positive patients only, those who underwent minimally invasive techniques had better scores in recreation and mood at 6 months only (P for both domains) compared to those who underwent open techniques. In p16-negative patients, appearance was the only significantly better domain among those who underwent minimally invasive techniques compared to open techniques (at 6 months only; P ). Fig. 1. Overall QOL by p16 status at each time point. [Color figure can be viewed in the online issue, which is available at patients, shoulder function was better in the chemoradiation group (P ); this difference resolved by 6 months posttreatment. There were no long-term differences in QOL for p16-negative patients treated with primary surgery versus chemoradiation. Patients who underwent primary surgical management were further stratified into two categories, open versus minimally invasive techniques that included use of either the robot or laser. Among all patients who underwent primary surgery, 26.7% (28/105) underwent minimally invasive surgery. Regardless of primary tumor site or p16 status, those who underwent minimally invasive techniques had better scores in chewing at 2 months (P ) and appearance at 6 months (P ) compared to those who underwent open DISCUSSION It is now recognized that patients with HPV-positive OPSCC have an improved survival when compared to their HPV-negative counterparts. 1,2 This improved survival is demonstrated in patients treated with both chemoradiation 1,4 and primary surgery, 5 including transoral robotic surgery 12 and transoral laser surgery. 13 With a growing number of HPV-positive OPSCC patients and a remarkable cure rate, their potential vulnerability to treatment intensity becomes more important, and the emphasis on QOL is thus essential to quantify. This is the first study to our knowledge that analyzes QOL using a validated survey and stratifying for both p16 status and primary treatment modality. Our findings reveal that QOL scores in each of 12 domains, including overall QOL, do not differ by primary treatment modality among the p16-positive OPSCC patients. In other words, there was no difference in QOL scores among those treated with primary surgery with or without adjuvant therapy compared to those treated with primary chemoradiation. Although only 30% of p16-positive patients underwent primary surgical Fig. 2. (a) Chewing by p16 status at each time point. (b) Speech by p16 status at each time point. (c) Swallowing by p16 status at each time point. (d) Saliva by p16 status at each time point. [Color figure can be viewed in the online issue, which is available at
5 management in our cohort, nearly all of those patients received adjuvant radiation. Even with double modality treatment, QOL was unaffected, suggesting that the addition of surgery has a minimal, if any, effect on longterm QOL scores in p16-positive patients. Furthermore, there were no QOL differences at 1 to 3 years posttreatment among the p16-positive patients managed with minimally invasive techniques versus open surgery. This apparent lack of QOL differences may, however, be due to small sample sizes after controlling for p16 status and treatment modality at each of the five time points. As expected, p16-positive patients in our study had better baseline and posttreatment QOL scores compared to p16-negative patients. This is most likely due to the fact that p16-positive patients are more often young, nonsmokers. 3 Investigators from the University of Washington demonstrated that baseline QOL scores were higher for HPV-positive patients compared to their HPVnegative counterparts. 19 They found a decrease in pretreatment to posttreatment QOL scores that was greater for the HPV-positive patients compared to the HPVnegative patients. By 1 year posttreatment, however, there was no association between HPV status and QOL. This is in contrast to our findings, which demonstrated that although overall QOL initially decreased for HPVpositive patients following treatment, it then returned to levels that were higher than baseline after 1 year posttreatment. They were also significantly better when compared to the HPV-negative cohort. Reasons for these discrepancies are unclear. In the study by Sharma et al., 19 the HPV-negative cohort was limited to patients with oropharyngeal or oral cavity squamous cell carcinoma. It is possible that our long-term QOL scores were lower for HPV-negative patients because other head and neck subsites were included. Of interest, the only domain in which HPV-positive patients fared worse than HPV-negative patients was in saliva. This is most likely attributable to the increased use of both primary and adjuvant radiation therapy among patients with HPV-positive compared to HPVnegative patients (95% versus 67%). Furthermore, the location of radiation exposure among OPSCC patients, who are more often HPV-positive, is more likely to involve the salivary glands than other subsites of the head and neck such as the larynx. Despite the initial discrepancy in posttreatment saliva scores among HPVpositive and HPV-negative patients, this difference became insignificant after 1 year of posttreatment QOL follow-up. With the advent of minimally invasive techniques to manage OPSCC, several investigators have analyzed QOL outcomes among patients treated with transoral robotic surgery (TORS) Two studies from Ohio State University on TORS patients revealed that QOL scores initially deteriorated after surgery in speech, eating, aesthetics, social disruption, and overall QOL. 20,23 However, they noted a return of QOL to high levels in all categories except for eating after 1 year posttreatment. 20,23 These studies utilized the Head and Neck Cancer Inventory HNCI grading system for QOL, which includes four domains. This is in contrast to the UW QOL v4 survey used in our study, which includes 12 domains and does not include eating as a distinct category. Swallowing, however, is a comparable UW- QOL v4 category; among our p16-positive patients, swallowing scores declined from an average baseline of 86 to 66 at 6 months posttreatment, but rebounded to 87 after 1 year posttreatment (Fig. 2c). Otherwise, our results among p16-positive patients parallel the findings in TORS cohorts, which contained approximately 84% to 85% p16-positive patients. 20,23 Our findings among the p16-positive patients are also similar to TORS trials in that overall QOL initially decreased from an average pretreatment score of 77 to a nadir of 57 at 2 months after treatment. The average overall QOL score then returned to even better than baseline at 82 (Fig. 1). A major difference between the prior investigations on TORS patients and our current study is that our cohort was stratified by p16 status and primary treatment modality. This stratification enabled us to conclude that primary surgery with adjuvant therapy does not lead to a difference in QOL compared to standard chemoradiation therapy among p16-positive patients. There are several limitations of our study that deserve mention. For one, to ensure a large sample size, patients were included if they completed at least one survey at a specified time period. It was not feasible to obtain serial QOL surveys from the same patient. In fact, only three patients responded to surveys at all five time periods. It is possible that patients who fared poorly were not well enough to go to their clinic visits, or even passed away following treatment would not have completed posttreatment surveys. This bias may have led to falsely elevated QOL scores, especially in the patients with HPV-negative head and neck cancer who were much more likely to recur or die from the disease during the study time period. While we estimate a very low number of deceased patients, we were unable to account for this in our methodology. Furthermore, 92.7% (164/177) of patients submitted surveys within their first year of posttreatment, which would likely reflect most of those with disease recurrence. In addition, there were not enough p16-positive, surgically treated patients to stratify by type of adjuvant therapy. Therefore, we were unable to determine a difference in QOL scores among those who received surgery alone, surgery plus radiation, and surgery plus chemoradiation. Since most patients (95%) underwent adjuvant therapy, we are able to conclude that QOL did not differ among those who underwent surgery plus adjuvant therapy versus chemoradiation alone. Similarly, age and other potential confounders were not controlled for in the QOL analysis at each time point because this would have further limited the sample size. A larger, prospectively mandated cohort and future deintensification of adjuvant therapy would allow for more in-depth stratification by treatment modality. CONCLUSION Ultimately, p16-positive patients in our cohort had better baseline and posttreatment overall QOL compared
6 to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Specifically, patients treated with primary surgery and adjuvant radiation had similar quality of life scores compared to those treated with primary chemoradiation, regardless of HPV/p16 status. BIBLIOGRAPHY 1. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363: Fakhry C, Westra WH, Lis S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100: Gillison ML, D Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100: Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010;16: Maxwell JH, Ferris RL, Gooding W, et al. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer 2013;119: Chaturvedi AK, Engels EA, Pfeiffe, RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29: Ernster JA, Sciotto CG, O Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 2007;117: Chenevert J, Chiosea S. Incidence of human papillomavirus in oropharyngeal squamous cell carcinomas: now and 50 years ago. Hum Pathol 2012;43: Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350: Bernier J. Chemoradiation in locally advanced head and neck cancer: new evidence, new challenges. Expert Rev Anticancer Ther 2004;4: Bernier J, Cooper JS, Pajak RF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC ( 22931) and RTOG ( 9501). Head Neck 2005;27: Cohen MA, Weinstein GS, O Malley BW Jr, Feldman M, Quon H. Transoral robotic surgery and human papillomavirus status: oncologic results. Head Neck 2011;33: Haughey BH, Hinni ML, Salassa JR, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 2011;33: Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010;116: D Cruz AK, Yueh B, Das AK, McDowell JA, Chaukar DA, Ernest AW. Validation of the University of Washington quality of life questionnaires for head and neck cancer patients in India. Indian J Cancer 2007;44: Vartanian JG, Carvalho AL, Yueh B, et al. Brazilian-Portuguese validation of the University of Washington Quality of Life Questionnaire for patients with head and neck cancer. Head Neck 2006;28: Rogers SN, Gwanne S, Lowe D, Humphris G, Yueh B, Weymuller EA Jr. The addition of mood and anxiety domains to the University of Washington quality of life scale. Head Neck 2002;24: El-Deiry MW, Futran ND, McDowell JA, Weymuller EA Jr. Influences and predictors of long-term quality of life in head and neck cancer survivors. Arch Otolaryngol Head Neck Surg 2009;135: Sharma A, Mendez E, Yueh B, et al. Human papillomavirus-positive oral cavity and oropharyngeal cancer patients do not have better quality-oflife trajectories. Otolaryngol Head Neck Surg 2012;146: Hurtuk AM, Marcinow A, Agrawal A, Old M, Teknos TN, Ozer E. Qualityof-life outcomes in transoral robotic surgery. Otolaryngol Head Neck Surg 2012;146: Leonhardt FD, Quon H, Abrahao M, O Malley BW Jr, Weinstein GS. Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function. Head Neck 2012;34: Sinclair CF, McColloch NL, Carroll WR, Rosenthal EL, Desmond RA, Magnuson JS. Patient-perceived and objective functional outcomes following transoral robotic surgery for early oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2011;137: Dziegielewski PT, Teknos TN, Durmus K, et al. Transoral robotic surgery for oropharyngeal cancer: long-term quality of life and functional outcomes. JAMA Otolaryngol Head Neck Surg 2013;10:1 9. doi: / jamaoto [Epub ahead of print]. 1597
Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer
Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer Dylan F. Roden, MD, MPH 1,2 ; David Schreiber, MD 2,3 ; and Babak Givi, MD 1,2 BACKGROUND: Concurrent chemoradiation (CCRT) and upfront
More informationThomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX
Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21
More informationTransoral Robotic Surgery (TORS) for Oropharyngeal Cancer
Transoral Robotic Surgery (TORS) for Oropharyngeal Cancer Ellie Maghami, MD, FACS Professor of Otolaryngology / Head and Neck Surgery Chief, Division of Head and Neck Surgery Norman and Sadie Lee Professor
More informationPredictive Accuracy of First Post-Treatment PET/CT in HPV-Related Oropharyngeal Squamous Cell Carcinoma
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Predictive Accuracy of First Post-Treatment in HPV-Related Oropharyngeal Squamous Cell Carcinoma Yekaterina
More informationTransoral Robotic Surgery and Adjuvant Therapy for Oropharyngeal Carcinomas and the Influence of p16 INK4a on Treatment Outcomes
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Transoral Robotic Surgery and Adjuvant Therapy for Oropharyngeal Carcinomas and the Influence of p16 INK4a
More informationHPV and Head and Neck Cancer: What it means for you and your patients
HPV and Head and Neck Cancer: What it means for you and your patients Financial Disclosure: None November 8, 2013 Steven J. Wang, MD Associate Professor Department of Otolaryngology-Head and Neck Surgery
More informationHPV-Related Head and Neck Squamous Cancers
2015 Wisconsin Comprehensive Cancer Control Summit Aligning Partners, Priorities, and the Plan HPV-Related Head and Neck Squamous Cancers MCW Department of Otolaryngology and Communication Sciences MCW
More informationHPV and Head and Neck Cancer
William C. Faquin, MD, PhD, FCAP Director, Head and Neck Pathology Massachusetts General Hospital Associate Professor of Pathology Harvard Medical School HPV and Head and Neck Cancer A number of testing
More informationClinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationHuman Papillomavirus and Head and Neck Cancer. Ed Stelow, MD
Human Papillomavirus and Head and Neck Cancer Ed Stelow, MD No conflict of interest Declaration Cancer 1974 Lancet Oncol 2016; 17: e477-8 JAMA 1984; 252: 1857 JAMA 1988;259(13):1943-1944 Clin Cancer Res
More informationHuman Papillomavirus Testing in Head and Neck Carcinomas
Human Papillomavirus Testing in Head and Neck Carcinomas Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine 12/18/2017 Overview
More informationOutcomes in Oncology
Outcomes in Oncology Ochsner Cancer Institute s Report to Physicians May 2014 ochsner.org/cancer Head and Neck Cancer Update: New Strategies for the Treatment of Oropharyngeal Cancer Dear Physicians, In
More informationHumaan Papillomavirus en hoofd/halskanker. Pol Specenier
Humaan Papillomavirus en hoofd/halskanker Pol Specenier pol.specenier@uza.be Humaan Papillomavirus en hoofd/halskanker Hoofd/halskanker: incidentie en oorzaken Oropharynx carcinoom Incidentie HPV HPV en
More informationDisclosure. Access 10/4/2013. The emerging role of TransOralRobotic Surgery (TORS) Organ preservation in the management of head and neck cancer
Disclosure The emerging role of TransOralRobotic Surgery (TORS) Intuitive Surgical, Inc. Proctor/Honoraria Eddie Méndez, MD, MS, FACS Associate Professor, Department of Otolaryngology: Head & Neck Surgery
More informationHPV/p16 Analyte Control
HPV/p16 Analyte Control Utility review and ring study results Colin Tristram, Director 2017 HPV/p16 Analyte Control Collaboration: Dr Max Robinson at Newcastle University a leading pathologist in head
More informationEffects of tumor staging and treatment modality on functional outcome and quality of life after treatment for laryngeal cancer
ORIGINAL ARTICLE Effects of tumor staging and treatment modality on functional outcome and quality of life after treatment for laryngeal cancer Stuart M. Robertson, FRCSGlasg(ORL-HNS), 1,2 * Justin C.
More informationA Systematic Review of Transoral Robotic Surgery and Radiotherapy for Early Oropharynx Cancer: A Systematic Review
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Systematic Review A Systematic Review of Transoral Robotic Surgery and Radiotherapy for Early Oropharynx
More informationPrevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer
ORIGINAL ARTICLE Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer Shamir P. Chandarana, MD, MSc, 1 Julia S. Lee, MS,
More informationCase Report Concurrent Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx in a Married Couple
Case Reports in Otolaryngology Volume 2016, Article ID 8481235, 4 pages http://dx.doi.org/10.1155/2016/8481235 Case Report Concurrent Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationUpdate on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12.
Update on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12. Non Cervical Cancers with an HPV aetiology 1. Anal 2. Penile 3. Vulval 4. Vaginal 5. Component of head
More informationEffect of Psychosocial Distress on Outcome for Head and Neck Cancer Patients Undergoing Radiation
The Laryngoscope VC 2017 The American Laryngological, Rhinological and Otological Society, Inc. Effect of Psychosocial Distress on Outcome for Head and Neck Cancer Patients Undergoing Radiation Allen M.
More informationSQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY IN THE ELDERLY
ORIGINAL ARTICLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY IN THE ELDERLY Yi-Shing Leu 1,2,3 *, Yi-Fang Chang 4, Jehn-Chuan Lee 1, Chung-Ji Liu 2,5,6, Hung-Tao Hsiao 7, Yu-Jen Chen 8, Hong-Wen Chen 8,9,
More informationIndications and techniques of surgery for the primary treatment of HNSCC
Prof. Christian Simon Chef-de-service Service d ORL et chirurgie cervico-faciale Centre Hospitalier Universitaire Vaudois (CHUV) Université de Lausanne Lausanne, Suisse Indications and techniques of surgery
More informationORIGINAL ARTICLE. Transoral Robotic-Assisted Surgery for Head and Neck Squamous Cell Carcinoma
ORIGINAL ARTICLE Transoral Robotic-Assisted Surgery for Head and Neck Squamous Cell Carcinoma One- and 2-Year Survival Analysis Hilliary N. White, MD; Eric J. Moore, MD; Eben L. Rosenthal, MD; William
More informationLymph node density as an independent prognostic factor in node-positive patients with tonsillar cancer
ORIGINAL ARTICLE Lymph node density as an independent prognostic factor in node-positive patients with tonsillar cancer Jun-Ook Park, MD, PhD, 1 Young-Hoon Joo, MD, PhD, 2 Kwang-Jae Cho, MD, PhD, 2 Min-Sik
More informationNew Chapter in Our Understanding of Human Papillomavirus-Related Head and Neck Cancer
Published Ahead of Print on September 15, 2014 as 10.1200/JCO.2014.56.5754 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2014.56.5754 JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A
More informationFirst of all, the pathophysiology
Welcome. My name is Eric Sturgis and I m a Professor in Head and Neck Surgery with a joint appointment in the Department of Epidemiology at The University of Texas MD Anderson Cancer Center. And today
More informationDoes Buccal Cancer Have Worse Prognosis Than Other Oral Cavity Cancers?
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Does Buccal Cancer Have Worse Prognosis Than Other Oral Cavity Cancers? P. Ryan Camilon, BA; William A. Stokes,
More informationSquamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations
Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations Troy G. Scroggins Jr. MD Chairman, Department of Radiation Oncology Ochsner Health Systems 1 Association of Postoperative Radiotherapy
More informationEarly adoption of transoral robotic surgical program: preliminary outcomes.
Thomas Jefferson University Jefferson Digital Commons Department of Otolaryngology - Head and Neck Surgery Faculty Papers Department of Otolaryngology - Head and Neck Surgery 9-1-2012 Early adoption of
More informationImaging Characteristics of Metastatic Nodes and Outcomes by HPV Status in Head and Neck Cancers
The Laryngoscope VC 2015 The American Laryngological, Rhinological and Otological Society, Inc. Imaging Characteristics of Metastatic Nodes and Outcomes by HPV Status in Head and Neck Cancers Akifumi Fujita,
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationLaryngeal Conservation
Laryngeal Conservation Sarah Rodriguez, MD Faculty Advisor: Shawn Newlands, MD, PhD The University of Texas Medical Branch Department of Otolaryngolgy Grand Rounds Presentation February 2005 Introduction
More informationHAVING prospectively administered
ORIGINAL ARTICLE Analysis of the Performance Characteristics of the University of Washington Quality of Life Instrument and Its Modification (UW-QOL-R) Ernest A. Weymuller, Jr, MD; Ramsey Alsarraf, MD,
More informationSurvival Benefit of Chemotherapy in Oropharyngeal Cancer Patients Treated with. Surgery and Post-Operative Radiation. Fawaz Mohammed Makki
Survival Benefit of Chemotherapy in Oropharyngeal Cancer Patients Treated with Surgery and Post-Operative Radiation by Fawaz Mohammed Makki A thesis submitted in partial fulfillment of the requirements
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationHead and Neck SCC. HPV in Tumors of the Head and Neck. Overview. Role of HPV in Pathogenesis of Head & Neck Tumors
HPV in Tumors of the Head and Neck Christina Kong, M.D. Associate Professor, Stanford Dept of Pathology Director, Cytopathology Laboratory & Cytopathology Fellowship ckong@stanford.edu Head and Neck SCC
More informationReporting HPV related carcinomas of the head and neck. dr. Nina Zidar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia
Reporting HPV related carcinomas of the head and neck dr. Nina Zidar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia Conflict of interest/funding X None Company: Product royalties
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationRadiotherapy Alone or Combined With Chemotherapy for Base of Tongue Squamous Cell Carcinoma
The Laryngoscope VC 2017 The American Laryngological, Rhinological and Otological Society, Inc. Radiotherapy Alone or Combined With Chemotherapy for Base of Tongue Squamous Cell Carcinoma Kaitlin Christopherson,
More informationORIGINAL ARTICLE. Predicting HPV Status in Head and Neck Cancer. The Predictive Value of Sociodemographic and Disease Characteristics
ORIGINAL ARTICLE Predicting HPV Status in Head and Neck Cancer The Predictive Value of Sociodemographic and Disease Characteristics J. Kenneth Byrd, MD; Christina S. T. Wilhoit, CCRP; M. Taylor Fordham,
More informationOriginal Article. KEYWORDS: head and neck cancer, lymph nodes, oral cancer, oropharyngeal cancer, squamous cell carcinoma, staging.
Original Article Number of Positive Nodes Is Superior to the Lymph Node Ratio and American Joint Committee on Cancer N Staging for the Prognosis of Surgically Treated Head and Neck Squamous Cell Carcinomas
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: Month XX, 2017 Report Length: 79 Pages
CADTH RAPID RESPONSE REPORT: SYSTEMATIC REVIEW Treatments for Locally Advanced Oropharyngeal Cancer: A Systematic Review of Clinical Effectiveness and Cost- Effectiveness Service Line: Rapid Response Service
More information1. Introduction This updated guidance sets out the preferred way for scoring and presenting the UW-QOL.
University of Washington Quality of Life Questionnaire (UW-QOL v4 and v4.1) Guidance for scoring and presentation Derek Lowe & Simon N Rogers (Updated 21-1-2018) 1. Introduction This updated guidance sets
More informationLARYNGEAL CANCER IN EGYPT: QUALITY OF LIFE MEASUREMENT WITH DIFFERENT TREATMENT MODALITIES
ORIGINAL ARTICLE LARYNGEAL CANCER IN EGYPT: QUALITY OF LIFE MEASUREMENT WITH DIFFERENT TREATMENT MODALITIES Ossama A. Hamid, MD, 1 Lobna M. El Fiky, MD, 1 Medani M. Medani, MD, 1 Ayman AbdelHady, MBBCh,
More informationTreatment for Supraglottic Ca History: : Total Laryngectomy y was routine until early 50 s, when XRT was developed Ogura and Som developed the one-sta
Role of Laser Therapy in Laryngeal Cancer Khalid Hussain AL-Qahtani MD,MSc,FRCS(c) MSc Assistant Professor Consultant of Otolaryngology Advance Head & Neck Oncology, Thyroid & Parathyroid,Microvascular
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationA Review of Multiple Hypothesis Testing in Otolaryngology Literature
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Systematic Review A Review of Multiple Hypothesis Testing in Otolaryngology Literature Erin M. Kirkham, MD,
More informationRising prevalence of human papillomavirus related oropharyngeal cancer in Australia over the last 2 decades
ORIGINAL ARTICLE Rising prevalence of human papillomavirus related oropharyngeal cancer in Australia over the last 2 decades Angela Hong, PhD, 1,2 * C. Soon Lee, MD, 1,3 Deanna Jones, BAppSci, 4 Anne-Sophie
More informationSurgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,
More informationORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence
ORIGINAL ARTICLE Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence Michael D. Kernohan, FDSRCS, FRCS, MSc; Jonathan R. Clark, FRACS; Kan Gao, BEng; Ardalan Ebrahimi, FRACS;
More informationLaryngeal Papillomatosis Associated Dysplasia in the Adult Population: An update on prevalence and HPV subtype
Laryngeal Papillomatosis Associated Dysplasia in the Adult Population: An update on prevalence and HPV subtype Taryn Davids MD, Susan Muller DMD MS, Justin Wise PhD, Michael M Johns III MD, Adam M Klein
More informationComparing Upper Airway Stimulation to Expansion Sphincter Pharyngoplasty: A Single University Experience
771395AORXXX10.1177/0003489418771395Annals of Otology, Rhinology & LaryngologyHuntley et al research-article2018 Original Article Comparing Upper Airway Stimulation to Expansion Sphincter Pharyngoplasty:
More informationDRAFT FOR CONSULTATION. Clinical Commissioning Policy Proposition: Robotic assisted trans-oral surgery for throat and voice box cancers
Clinical Commissioning Policy Proposition: Robotic assisted trans-oral surgery for throat and voice box cancers Information Reader Box (IRB) to be inserted on inside front cover for documents of 6 pages
More informationMANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS
MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS Kyle Arneson, MD PhD Avera Medical Group Radiation Oncology Avera Cancer Institute 16 th Annual Oncology Symposium September
More informationT1/T2 LARYNX CANCER. Click to edit Master Presentation Date. Thomas J Gernon, MD Otolaryngology-Head and Neck Surgery
ADVANCES IN TREATMENT OF T1/T2 LARYNX CANCER Click to edit Master Presentation Date Thomas J Gernon, MD Otolaryngology-Head and Neck Surgery I have nothing to disclose CHANGING TRENDS IN HNSCC GLOTTIC
More informationQuality of life outcome measures following partial glossectomy: Assessment using the UW-QOL scale
Original Article Free full text available from www.cancerjournal.net Quality of life outcome measures following partial glossectomy: Assessment using the UW-QOL scale R Kazi,, C Johnson, V Prasad, J De
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationHead and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S.
Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S. Associate Professor Division of Head and Neck Surgery Department of Otolaryngology-Head and
More informationThe Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer. William H.
The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer William H. Westra From the Department of Pathology and Otolaryngology/Head
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationHead and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
More informationThe management of advanced supraglottic and
ORIGINAL ARTICLE ORGAN PRESERVATION FOR ADVANCED LARYNGEAL CARCINOMA Robert L. Foote, MD, 1 R. Tyler Foote, 1 Paul D. Brown, MD, 1 Yolanda I. Garces, MD, 1 Scott H. Okuno, MD, 2 Scott E. Strome, MD 3 1
More informationPatterns of nodal metastasis and prognosis in human papillomavirus positive oropharyngeal squamous cell carcinoma
ORIGINAL ARTICLE Patterns of nodal metastasis and prognosis in human papillomavirus positive oropharyngeal squamous cell carcinoma Matthew E. Spector, MD, 1 K. Kelly Gallagher, MD, 1 Emily Bellile, MS,
More informationCost-effectiveness of transoral robotic surgery versus (chemo)radiotherapy for early T classification oropharyngeal carcinoma: A cost-utility analysis
ORIGINAL ARTICLE Cost-effectiveness of transoral robotic surgery versus (chemo)radiotherapy for early T classification oropharyngeal carcinoma: A cost-utility analysis John R. de Almeida, MD, MSc, 1 *
More informationHPV Analysis of Head and Neck Squamous Cell Carcinomas based on Fine-Needle. Aspiration Specimens. William H. Westra M.D.
HPV Analysis of Head and Neck Squamous Cell Carcinomas based on Fine-Needle Aspiration Specimens William H. Westra M.D. The Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore Maryland
More informationThe Growing Epidemic of HPV-Positive Oropharyngeal Carcinoma: A Clinical Review for Primary Care Providers
CLINICAL REVIEW The Growing Epidemic of HPV-Positive Oropharyngeal Carcinoma: A Clinical Review for Primary Care Providers Kevin A. Moore II, MD, and Vikas Mehta, MD While the rate of head and neck cancer
More informationObjectives. HPV Classification. The Connection Between Human Papillomavirus and Oropharyngeal Cancer 6/19/2012
The Connection Between Human Papillomavirus and Oropharyngeal Cancer Jennifer L. Cleveland, DDS, MPH Dental Officer/Epidemiologist OSAP Annual Symposium June 23, 2012 Atlanta, GA National Center for Chronic
More informationHypopharyngeal Cancer Incidence, Treatment, and Survival: Temporal Trends in the United States
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Hypopharyngeal Cancer Incidence, Treatment, and Survival: Temporal Trends in the United States Phoebe Kuo,
More informationLonger survival in patients with human papillomavirus related head and neck cancer after positive postradiation planned neck dissection
ORIGINAL ARTICLE Longer survival in patients with human papillomavirus related head and neck cancer after positive postradiation planned neck dissection Shao Hui Huang, MSc, MD, MRT(T), 1 Samip Patel,
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationOral Cavity and Oropharynx Cancer Trends
Oral Cavity and Oropharynx Cancer Trends Darien Weatherspoon, DDS, MPH Diplomate, American Board of Dental Public Health Program Officer, National Institute of Dental and Craniofacial Research National
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More informationAdvanced head and neck cancer: surgery and quality of life
AZIENDA U.L.S.S. 9 TREVISO - UNIVERSITA' DEGLI STUDI DI PADOVA STRUTTURA COMPLESSA CLINICIZZATA DI OTORINOLARINGOIATRIA Centro Regionale per l Oncologia Cervico-Facciale Direttore: Prof.ssa M.C. Da Mosto
More informationCyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer
Lin et al. Journal of Otolaryngology - Head and Neck Surgery 2013, 42:23 ORIGINAL RESEARCH ARTICLE Open Access Cyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer Rui Jun
More informationCopyright information:
Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy Sheela Hanasoge, Emory University Kelly
More informationGourin et al.: Long-Term Outcomes of Larynx Cancer Care in the Elderly
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Short- and Long-Term Outcomes of Laryngeal Cancer Care in the Elderly Christine G. Gourin, MD, MPH; Heather
More informationTransoral robotic total laryngectomy: Report of 3 cases
CASE REPORT Amy Chen, MD, Section Editor Transoral robotic total laryngectomy: Report of 3 cases Samuel Dowthwaite, MBBS, 1 Anthony C Nichols, MD, 1 John Yoo, MD, 1 Richard V. Smith, MD, 2 Sandeep Dhaliwal,
More informationTrends in oral and oropharyngeal (mouth) cancer incidence in Wales,
Trends in oral and oropharyngeal (mouth) cancer incidence in Wales, 2001-2013 November 2015 Dental Public Health Team, Public Health Wales Welsh Cancer Intelligence and Surveillance Unit, Public Health
More informationINDIAN JOURNAL OF CANCER
THE INDIAN JOURNAL OF CANCER ISSN 0019-509X Volume 44 Issue 4 October December 2007 C O N T E N T S EDITORIAL Indian needs stricter implementation... Pankaj Chaturvedi 129 ORIGINAL ARTICLES Point of sale
More informationHead & Neck Staging. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging
AJCC 8 th Edition Staging Head & Neck Staging Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving
More informationOutcomes for patients with head and neck squamous cell carcinoma presenting with N3 nodal disease
Witek et al. Cancers of the Head & Neck (2017) 2:8 DOI 10.1186/s41199-017-0027-z Cancers of the Head & Neck RESEARCH Open Access Outcomes for patients with head and neck squamous cell carcinoma presenting
More informationAJCC 8 th Edition Staging. Head & Neck Staging. Learning Objectives. This webinar is sponsored by. the Centers for Disease Control and Prevention.
AJCC 8 th Edition Staging Head & Neck Staging Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving
More informationAlberta Head and Neck Cancer Priority Setting Project
Alberta Head and Neck Cancer Priority Setting Project About You 1. Which group best describes you? (Check all that apply). * A person diagnosed with cancer of the head and neck A family member or caregiver
More informationPersistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer
THIEME Original Research 377 Persistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer Carlos Miguel Chiesa Estomba Frank Alberto Betances Reinoso
More informationComparison of Futility Monitoring Methods Using RTOG Clinical Trials. Q. Ed Zhang, PhD
Comparison of Futility Monitoring Methods Using RTOG Clinical Trials Q. Ed Zhang, PhD 1 Futility Monitoring Definition: Monitoring for early determination that trial results will not be in favor of H 1
More informationTransoral Laser Microsurgery (TLM) Adjuvant Therapy for Advanced Stage Oropharyngeal Cancer: Outcomes and Prognostic Factors
The Laryngoscope VC 2009 The American Laryngological, Rhinological and Otological Society, Inc. Transoral Laser Microsurgery (TLM) Adjuvant Therapy for Advanced Stage Oropharyngeal Cancer: Outcomes and
More informationThe Use of TORS for HPV-Related Oropharynx Cancer
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/the-use-of-tors-for-hpvrelated-oropharynx-cancer/7251/
More informationVOICE, SWALLOWING, AND QUALITY OF LIFE AFTER TOTAL LARYNGECTOMY RESULTS OF THE WEST OF SCOTLAND LARYNGECTOMY AUDIT
ORIGINAL ARTICLE VOICE, SWALLOWING, AND QUALITY OF LIFE AFTER TOTAL LARYNGECTOMY RESULTS OF THE WEST OF SCOTLAND LARYNGECTOMY AUDIT Stuart M. Robertson, FRCSGlasg(ORL-HNS), 1 Justin C. L. Yeo, MRCS, 1
More informationRESEARCH ARTICLE. Salvage Transoral Robotic Surgery for Recurrent or Residual Head and Neck Squamous Cell Carcinoma: A Single Institution Experience
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.17.7627 Salvage TORS for Recurrent or Residual Head Neck Cancer RESEARCH ARTICLE Salvage Transoral Robotic Surgery for Recurrent or Residual Head and Neck Squamous
More informationSquamous cell carcinoma of buccal mucosa: a 40-year review,,
Available online at www.sciencedirect.com American Journal of Otolaryngology Head and Neck Medicine and Surgery 33 (2012) 673 677 www.elsevier.com/locate/amjoto Squamous cell carcinoma of buccal mucosa:
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationBiomed Pap Med Fac Univ Palacky Olomouc Czech Repub Sep; 160(3):
Short-term postoperative distress associated with open vs. transoral robotic surgery () in patients with T1-T2 carcinomas of the tongue base and supraglottis Karel Slama a, David Slouka b, Jaroslav Slipka
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More information